Huibers, Anne
DePalo, Danielle K.
Perez, Matthew C.
Zager, Jonathan S.
Olofsson Bagge, Roger
Funding for this research was provided by:
Merck
Novartis Pharmaceuticals Corporation
Philogen
Castle Biosciences
Pfizer
Sun Pharma
Istari
Amgen
Delcath Systems
Provectus
Bristol-Myers Squibb
Endomagnetics Ltd
SkyLineDx
Roche
Pierre-Fabre
BD/BARD
Merck Sharp & Dohme
Roche and Sanofi Genzyme
SATMEG Ventures AB
University of Gothenburg
Article History
Received: 18 May 2023
Accepted: 18 September 2023
First Online: 16 October 2023
Declarations
:
: A.H., D.K.D. and M.C.P. declare no conflicts of interest. J.S.Z has advisory board relationships and has received fees from with Merck, Novartis, Philogen, Castle Biosciences, Pfizer, and Sun Pharma. He also received research funding from Istari, Amgen, Delcath Systems, Philogen, Provectus and Novartis. He serves on the medical advisory board for Delcath Systems. R.O.B. has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag) and SkyLineDx, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB.